J&J; gets subpoenas related to three drugs

Johnson & Johnson said it had received subpoenas from federal prosecutors in Philadelphia, Boston and San Francisco related to the sale and marketing of three drugs.

The drugs at issue are Risperdal, a treatment for schizophrenia and bipolar mania; the epilepsy treatment Topamax; and Natrecor, which is used to treat heart-failure patients, the New Brunswick, N.J., company said.

The investigations by the U.S. attorneys’ offices have been disclosed before. The latest subpoenas seek information about corporate supervision and oversight of J&J;’s Janssen, Ortho-McNeil and Scios subsidiaries, which sell the drugs, J&J; said.